FIRMS REQUESTING PRE-SUBMISSION MEETINGS SPECIFIED IN HOUSE FDA REFORM BILL MUST PROVIDE DETAILED PROTOCOLS; CDRH PREPARING FOR IMPLEMENTATION OF LEGISLATION
This article was originally published in The Gray Sheet
Executive Summary
Sponsors of premarket approval applications seeking a pre-submission meeting to gain feedback on clinical trial protocols must provide the agency with a detailed outline of proposed studies and background on company attendees at the meeting, according to the House Commerce Committee's Oct. 6 report on the stand-alone FDA device reform bill (HR 1710).
You may also be interested in...
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.